Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

NASDAQ:CNCE

Concert Pharmaceuticals, Inc.

Last Close

8.37

17/09 20:00

Market Cap

401.95M

Beta: 0.52

Volume Today

10.73M

Avg: 2.54M

PE Ratio

−4.67

PFCF: −4.82